2022³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö(1ÀÏÂ÷) : 2022-04-08±³À°ÀÏÀÚ : 2022-04-08
±³À°Àå¼Ò : ¿öÄ¿ÈúÈ£ÅÚ, ¼¿ï
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ ÇÏÀ̺긮µå) 2022³â Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö(1ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ³»ºÐºñÇÐȸ
¿¬¶ôó : 02-714-2428
À̸ÞÀÏ :
endo@endocrinology.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 28 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í Àü¹®ÀÇ/ÀüÀÓÀÇ/±³¼ö/°³¿øÀÇ/±âÃÊÀÇÇÐÀÚ : 10¸¸¿ø (ºñȸ¿ø 15¸¸¿ø) Àü°øÀÇ/´ëÇпø»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/°£È£»ç/¿µ¾ç»ç/ÀÇ·á±â»ç/±âŸ : 5¸¸¿ø (ºñȸ¿ø 7¸¸¿ø) *¸¸ 65¼¼ ÀÌ»ó Æò»ýȸ¿ø : ¹«·á **Àü°øÀÇ, ´ëÇпø»ýÀ» Á¦¿ÜÇÑ Çлý : ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-08 Room 1 09:00~09:15 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: ºÎ½Å Áúȯ ºÐ¾ß ±è¼º¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 09:15~09:30 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: ´ç´¢º´ ºÐ¾ß ¹Ú°æ¼ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 09:30~09:45 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: Ä®½· ¹× °ñ´ë»ç ºÐ¾ß ½ÅÂù¼ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 09:45~10:00 ³²°î ¹ÎÇå±â ±³¼öÀÇ ¹ßÀÚÃë: ³úÇϼöü Áúȯ ºÐ¾ß ±è¹Î¼±(¿ï»êÀÇ´ë)
Åä·Ð 04-08 Room 1 10:00~10:30 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 2 09:00~09:20 Iso-dehydrozingerone Blocks RANKL-induced Differentiation of Monocyte/macrophage Lineage to Osteoclast by the Extreme Activation of NF-¥êB ¹Ú±æÈ«(°í·ÁÀÇ´ë »ýÈÇкÐÀÚ»ý¹°Çб³½Ç)
±³À°½Ã°£ 04-08 Room 2 09:20~09:40 Bone Regeneration Using Bioceramics and Bioactive Molecules ¹ÚÀDZÕ(°æºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°º´¸®ÇÐ ¹× Àç»ýÀÇÇб³½Ç)
±³À°½Ã°£ 04-08 Room 2 09:40~10:00 Biomaterials-based Delivery of Signaling Molecules and Cells for Bone Tissue Engineering ½ÅÈï¼ö(ÇѾç´ëÇб³ »ý¸í°øÇаú)
Åä·Ð 04-08 Room 2 10:00~10:30 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 3 09:00~09:20 Precision Diagnosis of Diabetic Complication Using Exosomal Multi-omics ·ù¼ºÈ£(¼øõÇâÀÇ´ë SIMS)
±³À°½Ã°£ 04-08 Room 3 09:20~09:40 ´ç´¢º´¼º½ÅÁõ¿¡¼ ¼Òº¯ ¼¼Æ÷¹Û ¼ÒÆ÷ü miRNA ÇÁ·ÎÆÄÀϸµ ¹× ³×Æ®¿öÅ© °æ·ÎºÐ¼® ÀÌ´ëÈ£(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 04-08 Room 3 09:40~10:00 Effect of Salivary Exosomal miRNA on Periodontitis with Insulin Resistance ÀÌÇö½Â(Ãæ³²ÀÇ´ë)
Åä·Ð 04-08 Room 3 10:00~10:30 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 4 09:00~09:20 Metformin and Aging ±èÇýÁø(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-08 Room 4 09:20~09:40 Hormone Treatment of Postmenopausal Women äÈñµ¿(¿ï»êÀÇ´ë »êºÎÀΰú)
±³À°½Ã°£ 04-08 Room 4 09:40~10:00 Melatonin and Aging ±è¹Ì°æ(ÀÎÁ¦ÀÇ´ë)
Åä·Ð 04-08 Room 4 10:00~10:30 Åä·Ð ()
ÈÞ½Ä 04-08 10:30~10:40 ÈÞ½Ä ()
±³À°½Ã°£ 04-08 Room 1 10:40~11:00 COVID-19¿Í °©»ó¼±Áúȯ ±ÇÇý¹Ì(°ºÏ»ï¼ºº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-08 Room 1 11:00~11:20 °©»ó¼±ÃÊÀ½ÆÄ ±Þ¿©È ÇѼö¿¬(»ï¼º¼¿ïº´¿ø ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04-08 Room 1 11:20~11:40 Radiation Hazard of Radioiodine Therapy: Emotion and Science ÆØÁøö(¼¿ï´ëº´¿ø ÇÙÀÇÇаú)
Åä·Ð 04-08 Room 1 11:40~12:10 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 2 10:40~11:00 Biochemical Mechanisms of Fuel Metabolism and the Physiological Relevance in Human Diseases ÃÖµ¿¿í(Ãæ³²´ë »ýÈÇÐ)
±³À°½Ã°£ 04-08 Room 2 11:00~11:20 Developmental Programming of Immunity and Metabolism by Perinatal Endocrine Signal È«ÁØ¿µ(¿¬¼¼´ëÇб³ »ý¸í°øÇÐ)
±³À°½Ã°£ 04-08 Room 2 11:20~11:40 Irisin, its Receptor and the Links between Exercise and Health ±èÇö¿ì(Harvard Medical School / 3¿ù KAIST »ý¸í°úÇаú ÀÓ¿ë)
Åä·Ð 04-08 Room 2 11:40~12:10 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 3 10:40~11:00 Update on the ADA Diabetes Treatment Guideline 2022 Á¤Ã¢Èñ(¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 04-08 Room 3 11:00~11:20 Efficacy and Safety of Evogliptin in Patients with Type2 Diabetes and Non-alcoholic Fatty Liver Disease ÇãÁöÇý(ÇѸ²ÀÇ´ë ÆòÃ̼º½Éº´¿ø)
±³À°½Ã°£ 04-08 Room 3 11:20~11:40 Combination therapy of oral antidiabetic drugs involving evogliptin and the risk of cardiovascular events in patients with type 2 diabetes mellitus ±è³²ÈÆ(°í·ÁÀÇ´ë °í´ë¾È¾Ïº´¿ø)
Åä·Ð 04-08 Room 3 11:40~12:10 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 4 10:40~11:00 Genetic Approach to Skeletal Dysplasia °íÁ¤¹Î(¼¿ïÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 04-08 Room 4 11:00~11:20 Treatment of FGF23-related Hypophosphatemic Diseases À̽ÂÇö(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-08 Room 4 11:20~11:40 Hypophosphatasia ¹®ÁØÈ£(¼¿ïÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 04-08 Room 4 11:40~12:10 Åä·Ð ()
ÈÞ½Ä 04-08 12:10~12:20 ÈÞ½Ä ()
±³À°½Ã°£ 04-08 Room 1 12:20~12:40 My Clinical Experiences of Evolocumab in Endocrinology ½Åµ¿¿±(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 04-08 Room 1 12:40~13:00 Clinical Significance of TIR and the Latest Comparative Study of Second-generation Basal Insulin ±è±Ô¸®(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-08 Room 2 12:20~12:40 How to find the Optimal Combination Therapy for Patients with Type 2 Diabetes À̽Âȯ(°¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 04-08 Room 2 12:40~13:00 New Lipid Therapy Option for Low & Moderate Risk ASCVD Patients ±è»ó¿ë(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 04-08 Room 3 12:20~12:40 KDA/ADA ÃֽŠÁø·áÁöħ°ú ÇÔ²² »ìÆì º» Ç÷´çº¯µ¿¼º °ü¸®ÀÇ Á߿伺 Ãְ湬(°í·ÁÀÇ´ë °í´ë±¸·Îº´¿ø)
±³À°½Ã°£ 04-08 Room 3 12:40~13:00 Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy ÀÌÀçÇõ(ÇѾçÀÇ´ë ¸íÁöº´¿ø ³»ºÐºñ³»°ú)
½Ä»ç 04-08 13:00~13:20 ½Ä»ç ()
ÈÞ½Ä 04-08 13:20~13:40 ÈÞ½Ä ()
±³À°½Ã°£ 04-08 Room 1 13:40~14:20 Role of Lysosomal Stress & Lysosome Stress Response in Metabolic Syndrome and Diabetes À̸í½Ä(¼øõÇâ´ëÇб³ ÀÇ»ý¸í¿¬±¸¿ø (SIMS) (¼®Á ±³¼ö))
±³À°½Ã°£ 04-08 Room 1 14:20~14:40 My Journey to (Para)thyroid Diseases À̽ÃÈÆ(°¡ÃµÀÇ´ë)
ÈÞ½Ä 04-08 14:40~14:50 ÈÞ½Ä ()
±³À°½Ã°£ 04-08 Room 1 14:50~15:10 Super-hero Antibodies against Osteoporosis (Efficacy of Denosumab and Romosozumab) ¾È¼ºÈñ(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 15:10~15:30 Questions and Facts Regarding Denosumab Discontinuation ±è¹üÁØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 15:30~15:50 Real-world Effectiveness of Romosozumab with Case Review È«³²±â(¿¬¼¼ÀÇ´ë)
Åä·Ð 04-08 Room 1 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 2 14:50~15:05 ¼Ò¾Æ¿¡¼ÀÇ ¿©¼ºÇü À¯¹æÀÇ ÀÓ»óÀû ÀÇ¹Ì - ¼ºÁ¶¼÷Áõ°ú ¿©¼ºÇü À¯¹æ äÇö¿í(¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø ¼Ò¾Æ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-08 Room 2 15:05~15:20 ¿©¼ºÇü À¯¹æÀÇ ¿µ»óÀÇÇÐÀû Áø´Ü À±Á¤Çö(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 04-08 Room 2 15:20~15:35 Evaluation and Management of Gynecomastia in Adults °ø¼ºÇý(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-08 Room 2 15:35~15:50 ¿©¼ºÇüÀ¯¹æÁõ ¼ö¼úÀû Ä¡·áÀÇ ÃÖ½ÅÁö°ß ¹ÎÈ£±Õ(À¯¹Ì³ë ¿Ü°úÀÇ¿ø)
Åä·Ð 04-08 Room 2 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 3 14:50~15:10 Best Candidate Patients for Abs & siRNA against PCSK9 ÀÌ¿øÀç(¼¿ïÀÇ´ë ºÐ´ç¼¿ï´ëº´¿ø ¼øȯ±â³»°ú)
±³À°½Ã°£ 04-08 Room 3 15:10~15:30 New Modulators of LDLR-independent Pathways ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 04-08 Room 3 15:30~15:50 Metabolic Consequences of New Lipid Lowering Drugs: Good or Bad? ¼¼ºÈ¯(µ¿¾ÆÀÇ´ë µ¿¾Æ´ëº´¿ø ³»ºÐºñ³»°ú)
Åä·Ð 04-08 Room 3 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 4 14:50~15:10 Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 04-08 Room 4 15:10~15:30 Liver X Receptor ¥â Related to Tumor Progression and Ribosome Gene Expression in Papillary Thyroid Cancer Á¶¿µ¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-08 Room 4 15:30~15:50 Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study ¹®Áؼº(¿µ³²ÀÇ´ë)
Åä·Ð 04-08 Room 4 15:50~16:20 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 5 14:50~15:10 Obesity Clinic Setting ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-08 Room 5 15:10~15:30 Use of DXA for Body Composition ±èųâ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 04-08 Room 5 15:30~15:50 Use of Bioelectrical Impedance Analysis ÀÓ¼ö(¼¿ïÀÇ´ë)
Åä·Ð 04-08 Room 5 15:50~16:20 Åä·Ð ()
ÈÞ½Ä 04-08 16:20~16:30 ÈÞ½Ä ()
±³À°½Ã°£ 04-08 Room 1 16:30~16:50 ³»ºÐºñÇÐȸÀÇ ¿ª»ç ¡®40³â»ç¡¯ ±èµ¿¼±(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 16:50~17:10 ³»ºÐºñÇÐȸÀÇ ¾÷Àû ¡®40³â°£ÀÇ Çй®Àû ¼ºÃ롯 ÀÌÀºÁ÷(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-08 Room 1 17:10~17:30 ³»ºÐºñÇÐȸÀÇ ¹Ì·¡ ¡®¿ì¸®°¡ °¡¾ß Çұ桯 À¯¼øÁý(°¡Å縯ÀÇ´ë)
Åä·Ð 04-08 Room 1 17:30~18:00 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 2 16:30~16:50 How DPP4Is May Address the Treatment Strategies ¿ÀÅÂÁ¤(¼¿ïÀÇ´ë ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 04-08 Room 2 16:50~17:10 Keep Your Confidence on Type 2 DM in Broad Range of Patients ±èÇý¼ø(°è¸íÀÇ´ë °è¸í´ëÇб³ µ¿»êº´¿ø)
±³À°½Ã°£ 04-08 Room 2 17:10~17:30 The Latest Evidence of SGLT2 Inhibitors for Patients with Type 2 Diabetes ¹Ú¼¼Àº(¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø)
Åä·Ð 04-08 Room 2 17:30~18:00 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 3 16:30~17:00 °©»ó¼±ÀÚ°¡Ç×ü°¡ ÀӽŠ¹× ÀӽŠÇÕº´Áõ¿¡ ¹ÌÄ¡´Â ¿µÇâ ±èÁøÈ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 04-08 Room 3 17:00~17:30 ÀӽŠÀüÈÄ °©»ó¼±±â´ÉÀúÇÏÁõÀÇ Áø´Ü ¹× Ä¡·á ¾ÈÈ¿µ(Áß¾ÓÀÇ´ë)
Åä·Ð 04-08 Room 3 17:30~18:00 Åä·Ð ()
±³À°½Ã°£ 04-08 Room 5 16:30~16:50 Appetite Regulation: Role of Brain and Peripheral Signals in Obesity ³ëÀº(°í·ÁÀÇ´ë °í·Á´ëÇб³ ±¸·Îº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 04-08 Room 5 16:50~17:10 Role of Phentermine and Qsymia in Obesity Management ±èº¸¿¬(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04-08 Room 5 17:10~17:30 Role of Incretin-based Therapy in Obesity Management: Liraglutide, Semaglutide, Tirzepatide ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë)
Åä·Ð 04-08 Room 5 17:30~18:00 Åä·Ð ()